Our aim is to improve Global Health through excellence in research focusing in Malaria (with a special emphasis on Malaria Elimination), Chagas disease, HIV/AIDS and Sexually Transmitted Infections, Viral and Bacterial Infections (mostly Antibiotic Resistance), and Maternal, Child and Reproductive Health. We are also increasingly involved in research on Population Movements and Health (including emerging health threats such as Ebola, dengue and chikungunya), leishmaniasis and tuberculosis.
Where Do We Come From?
When Barcelona's Hospital Clínic created Spain's first tropical medicine unit in 1984, it laid the groundwork for the introduction and the development of this field in the country. Building on this base, in 2006 we founded the Barcelona Centre for International Health Research (CRESIB), which four years later became a national and international reference in global health. CRESIB was also the cornerstone for the creation of the Barcelona Institute for Global Health (ISGlobal) in 2010. With the creation of ISGlobal, the task of treating tropical diseases was complemented and supported not only by the knowledge generated through research but also by the transfer of this knowledge to society.
In 2014, the CRESIB Board of Trustees approved the dissolution of CRESIB as a separate legal entity and set in motion the full integration of the centre's research activity into ISGlobal in 2015. In a parallel process, CRESIB's accreditation as a CERCA research centre will also be transferred to ISGlobal.
How Do We Do It?
We promote multidisciplinary, translational and cross-cutting research in order to maximize our impact.
We currently have the following research programmes:
o Enabling technologies for malaria research
o Parasite biology
o Malaria immunology
o Evaluation of preventive and therapeutic tools
o Epidemiology and clinical presentation of Plasmodium falciparum and Plasmodium vivax
o Vector biology and control
o Novel approaches and strategies for malaria elimination
o Epidemiology of Chagas disease in non-endemic areas
o Biomarkers for therapeutic efficacy in treated patients and early diagnosis of cardiac damage in patients with Chagas disease
o Clinical trials for new drugs to treat Chagas disease parasitologically
o Studies on the pharmacokinetics of benznidazole
o HIV and maternal and child health
o Pathogenesis of acute and early HIV infection
o Community epidemiology studies to inform future HIV-prevention interventions
o Immune reconstitution inflammatory syndrome (IRIS)
o Vaccination response in HIV-infected patients
o HIV testing modalities
o Pathology of premalignant and malignant lesions related to human papillomavirus infections
o Malaria in pregnancy
o Operational research on the acceptability and feasibility of the implementation of a human papillomavirus (HPV) vaccination programme for preadolescent girls in Africa.
o Pharmacovigilance studies of antiretroviral and antimalarial drugs in pregnant women
o Aetiology and risk factors for anaemia in children
In addition, we have an Emerging Activities programme which acts as an incubator for activities that could eventually lead to a new research programme.
o Populations movements and health, including emerging health threats such as Ebola, Dengue, Chikungunya and others.
o Causes of death in low-income countries
ISGlobal has a Scientific and Technical Advisory Committee whose main task is to assess scientific activities, research programmes and the strategic plan. The committee is also responsible for evaluating the institute's faculty researchers.
Where Do We Do It?
Although our headquarters are in Barcelona, ISGlobal's activity is global in scope. In addition to the countries where we are currently taking part in research projects, we mantain a stable presence in Africa and Latin America through three research platforms: